Otonomy to Participate in Two Upcoming Investor Conferences

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management is scheduled to participate in two upcoming virtual investor conferences.

  • Evercore ISI 3rd Annual HealthCONx Conference: presentation on December 1, 2020 at 3:05 p.m. ET / 12:05 p.m. PT. A live audio webcast of the presentation will be available through the Events page of the company’s website at www.otonomy.com and an archived replay will be available shortly after the event.
  • Piper Sandler 32nd Annual Healthcare Conference: 1 on 1 investor meetings on December 2, 2020. A pre-recorded fireside chat will be accessible from November 23 to December 3, 2020 through the Events page of the company’s website at www.otonomy.com.

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.

Contacts:

Media Inquiries
Spectrum Science
Chloé-Anne Ramsey
Vice President
404.865.3601
cramsey@spectrumscience.com

Investor Inquiries
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com  

Staff

Recent Posts

Medsien Launches Fully Managed Advanced Primary Care Management (APCM) Solution to Power the Next Generation of Primary Care

Medsien's Advanced Primary Care Management (APCM) program transforms chronic care with fast deployment, smart automation…

2 days ago

Hemostemix Closes $469,366 Private Placement

Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…

2 days ago

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr.…

2 days ago

Virbac : Declaration of the number of shares and voting rights 06/2025

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of…

2 days ago